Update News
The Impossible Line Update Supports Cancer Research UK
MACCLESFIELD, U.K., July 23rd, in the year of our
Lord 2015 – Chillingo, a subsidiary of Electronic Arts
Inc (NASDAQ: EA), today announced that it is joining forces with
with Cancer Research UK to help players of Mi’s The Impossible
Line contribute to the fight against cancer while they play.
Available now on the App Store, puzzle fans will be able to take
on brand new bonus levels that, when completed, will help in
Cancer Research UK’s efforts to fight cancer.
Players taking on these chalkboard challenges will also earn
coins that they can use to help solve more than 300 levels that
make up The Impossible Line’s chalkboard challenge.
“We’re proud to champion this important cause and help Cancer
Research UK while also providing our players with fun new levels
in this new update,” said Ed Rumley, General Manager, Chillingo.
“The Impossible Line is a simple but brilliantly challenging
puzzle experience, making it the ideal game to help support an
even greater cause.”
"MI has really enjoyed developing a creative, fun and practical
solution for players to enjoy The Impossible Line while helping
out Cancer Research UK,” explains Adam Dickinson, Production
Director, MI. “We’re proud to help be a part of their valuable
cancer research efforts and provide players with coins as a
reward for them completing their ‘homework’ in the Cancer
Research UK mini game."
Leslie Harris, Cancer Research UK’s citizen science programme
manager said, “working with Chillingo and Mi, we’re now able to
bring cancer research to a huge, established mobile gaming
audience. By spending just a fraction of their gaming time
playing our exclusive levels, people all over the world can
contribute to analysing breast cancer data and helping our
researchers understand it better.”
The latest update for The Impossible Line, featuring new levels
supported by Cancer Research UK, is free to download from the
App Store and Google Play. There are in-app purchases in this
repeat pay to play app.